Eikon Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	104.9	129.18	112.78
Short-Term Investments	231.07	90.93	317.63
Cash & Short-Term Investments	335.98	220.11	430.41
Cash Growth	52.64%	-48.86%	-
Prepaid Expenses	12.54	7.38	6.01
Restricted Cash	0.4	0.4	-
Total Current Assets	348.92	227.89	436.43
Property, Plant & Equipment	233.86	259.13	86.88
Long-Term Deferred Charges	3.6	-	-
Other Long-Term Assets	8.35	4.22	2.4
Total Assets	594.73	491.24	525.71
Accounts Payable	0.68	17.58	2.19
Accrued Expenses	44.16	29.16	21
Current Portion of Leases	10.03	9.31	5.05
Other Current Liabilities	0.14	0.4	3.21
Total Current Liabilities	55.01	56.45	31.44
Long-Term Leases	247.29	193.15	26.69
Other Long-Term Liabilities	10	5.35	0.73
Total Liabilities	312.3	254.95	58.86
Common Stock	-	-	0
Additional Paid-In Capital	41.48	33.01	19.75
Retained Earnings	-920.51	-604.94	-361.13
Total Common Equity	-879.03	-571.93	-341.37
Shareholders' Equity	282.44	236.29	466.85
Total Liabilities & Equity	594.73	491.24	525.71
Total Debt	257.32	202.46	31.74
Net Cash (Debt)	78.66	17.65	398.68
Net Cash Growth	345.59%	-95.57%	-
Net Cash Per Share	27.18	7.01	196.75
Filing Date Shares Outstanding	54.14	2.87	2.03
Total Common Shares Outstanding	3.07	2.87	2.03
Working Capital	293.91	171.44	404.99
Book Value Per Share	-286.47	-199.28	-168.47
Tangible Book Value	-879.03	-571.93	-341.37
Tangible Book Value Per Share	-286.47	-199.28	-168.47
Machinery	58.97	54.36	49.47
Construction In Progress	0.62	96.86	5.42
Leasehold Improvements	120.59	18.61	18.34

Updated Jan 9, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q